DCTH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

22.80M

+103.57%

-0.055

-50%

19.99M

+32.37%

0.048

+58.33%

25.28M

+27.75%

0.055

-21.43%

Estimates Revision

The market is revising No Change the revenue expectations for Delcath Systems, Inc. (DCTH) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -1.15%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-1.15%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast DCTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCTH is 25.50 USD with a low forecast of 21.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

25.50

High

30.00

Current: 0.000

Low

21.00

Averages

25.50

High

30.00

Clear Street

Buy

maintain

$28 -> $29

2026-01-09

New

Reason

Clear Street

Price Target

$28 -> $29

2026-01-09

New

maintain

Buy

Reason

Clear Street raised the firm's price target on Delcath Systems to $29 from $28 and keeps a Buy rating on the shares after the company announced preliminary Q4 results. Hepzato is now a "steady contributor for Delcath, with quarter-to-quarter variability more predictable, growth still available, and cash flow to fund expansion indications, the analyst tells investors in a research note.

Craig-Hallum

Chase Knickerbocker

Buy

downgrade

$24 -> $20

2025-10-21

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$24 -> $20

2025-10-21

downgrade

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker lowered the firm's price target on Delcath Systems to $20 from $24 and keeps a Buy rating on the shares following the company's prerelease/guidance and CHOPIN data at ESMO. Phase 2 CHOPIN study data presented at ESMO showed a clear benefit for Chemosat/Hepzato combined with checkpoint inhibitors in metastatic uveal melanoma. However, this news was overshadowed by disappointing Q3 and FY25 guidance, with Q3 revenue guided to $20.5M and FY25 revenue to $83M-$85M, the firm says. Craig-Hallum expects the CHOPIN data to inform U.S. use of Hepzato in sequence with checkpoint inhibitors, potentially driving increased volume in the second half of 2026.

H.C. Wainwright

Buy

downgrade

$31 -> $30

2025-10-20

Reason

H.C. Wainwright

Price Target

$31 -> $30

2025-10-20

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Delcath Systems to $30 from $31 and keeps a Buy rating on the shares after the company issued preliminary Q3 financial results and lowered revenue guidance for FY2025. Additionally, Delcath presented a clinical data update from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 annual Congress of European Society for Medical Oncology, notably that the clinical study met its primary endpoint of improved one-year progression-free survival.

Clear Street

Buy

maintain

$27 -> $28

2025-10-20

Reason

Clear Street

Price Target

$27 -> $28

2025-10-20

maintain

Buy

Reason

Clear Street raised the firm's price target on Delcath Systems to $28 from $27 and keeps a Buy rating on the shares. The stock is trading lower on the company's "soft" preliminary Q3 results and 2025 revenue guidance, the analyst tells investors in a research note. However, the firm attributes the results to pricing dynamics and new patient starts, which it feels are "likely a blip." The CHOPIN trial results will lead to increased penetration of Hpezato into the metastatic uveal melanoma population, contends Clear Street. The firm sees today's selloff as a buying opportunity. The stock is down 5% to $11.38 in midday trading.

H.C. Wainwright

Buy

maintain

$29 -> $31

2025-08-07

Reason

H.C. Wainwright

Price Target

$29 -> $31

2025-08-07

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Delcath Systems to $31 from $29 and keeps a Buy rating on the shares following the Q2 report. The firm says robust Hepzato adoption continues to drive growth.

H.C. Wainwright

Buy

maintain

$24 -> $29

2025-05-23

Reason

H.C. Wainwright

Price Target

$24 -> $29

2025-05-23

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Delcath Systems to $29 from $24 and keeps a Buy rating on the shares after the company announced its intention to enter into a Medicaid National Drug Rebate agreement. This strategic move is prudent given that it could not only aid in accessing a larger patient base but also help in achieving sustainable growth, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Delcath Systems Inc (DCTH.O) is 68.62, compared to its 5-year average forward P/E of -2.79. For a more detailed relative valuation and DCF analysis to assess Delcath Systems Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.79

Current PE

68.62

Overvalued PE

59.53

Undervalued PE

-65.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.65

Current EV/EBITDA

17.92

Overvalued EV/EBITDA

23.10

Undervalued EV/EBITDA

-34.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

14.38

Current PS

3.46

Overvalued PS

29.36

Undervalued PS

-0.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DCTH News & Events

Events Timeline

No data

News

9.5

01-09Newsfilter

PinnedDelcath Systems Reports Preliminary 2025 Revenue of $85.2 Million

7.5

01-06Benzinga

Three Microcap Companies Show Healthy Growth: OPXS, DCTH, MAMA

9.0

01-02NASDAQ.COM

Delcath's HEPZATO KIT Shows Consistent Tumor Responses, Q3 Revenue Hits $19.3 Million

People Also Watch

Frequently Asked Questions

What is Delcath Systems Inc (DCTH) stock price today?

The current price of DCTH is 10.34 USD — it has increased 1.27 % in the last trading day.

What is Delcath Systems Inc (DCTH)'s business?

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

What is the price predicton of DCTH Stock?

What is Delcath Systems Inc (DCTH)'s revenue for the last quarter?

Delcath Systems Inc revenue for the last quarter amounts to 20.56M USD, increased 83.60 % YoY.

What is Delcath Systems Inc (DCTH)'s earnings per share (EPS) for the last quarter?

Delcath Systems Inc. EPS for the last quarter amounts to 0.02 USD, decreased -66.67 % YoY.

What changes have occurred in the market's expectations for Delcath Systems Inc (DCTH)'s fundamentals?

How many employees does Delcath Systems Inc (DCTH). have?

Delcath Systems Inc (DCTH) has 96 emplpoyees as of January 10 2026.

What is Delcath Systems Inc (DCTH) market cap?

Today DCTH has the market capitalization of 365.14M USD.